Search Grant Opportunities

Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional)

ID: PAR-24-106 • Type: Posted

Description

The purpose of this notice of funding opportunity (NOFO) is to support applications from small businesses to develop solutions for commercialization that enable regional genomic medicine eConsult Service.
Background
The National Institutes of Health (NIH) and the National Human Genome Research Institute (NHGRI) are issuing a notice of funding opportunity (NOFO) to solicit Small Business Innovation Research (SBIR) grant applications from small businesses. The purpose of this NOFO is to support the development of innovative solutions for commercialization that would enable regional genomic medicine eConsult Services.

Grant Details
The NOFO invites applications from eligible small businesses to develop solutions for commercialization that can be used to enable regional clinician-to-clinician genomic medicine eConsult services. The solutions should address barriers to setting up eConsult services, conducting outreach, promotion, and education about eConsult services, and/or providing eConsults. The solutions should reduce costs, time, and/or increase access to regional genomic medicine eConsult services. The NOFO also outlines specific objectives and defines the terms 'Electronic consults (eConsults)' and 'Regional eConsult services'.

Eligibility Requirements
Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity. SBCs must meet specific criteria related to their organization, ownership, and number of employees. Additionally, SBCs must comply with the Phase I to Phase II Transition Rate Benchmark and Phase II to Commercialization Benchmark requirements.

Period of Performance
The project period can be up to 2 years for Phase I and up to 3 years for Phase II. The earliest start date is May 30, 2024, with an expiration date of May 31, 2024.

Grant Value
Budgets up to $400,000 total costs for Phase I and up to $2,150,000 total costs for Phase II may be requested. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.

Place of Performance
The grant is open only to United States small business concerns (SBCs), with a place of business located in the United States.

Overview

Category of Funding
Health
Funding Instruments
Grant
Grant Program (CFDA)
Grant Category
Discretionary
Cost Sharing / Matching Requirement
False
Source
On 1/9/24 the National Institutes of Health posted grant opportunity PAR-24-106 for Solutions to Enable Regional Genomic Medicine eConsult Services (R43/R44 Clinical Trial Optional). The grant will be issued under grant program 93.172 Human Genome Research.

Timing

Posted Date
Jan. 9, 2024, 12:00 a.m. EST
Closing Date
May 30, 2024, 12:00 a.m. EDT Past Due
Last Updated
Jan. 9, 2024, 2:34 p.m. EST
Version
1
Archive Date
July 5, 2024

Eligibility

Eligible Applicants
Small businesses
Additional Info
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed.

Contacts

Contact
National Institutes of Health
Contact Email
Email Description
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Contact Phone
(301) 402-2541
Additional Information
https://grants.nih.gov/grants/guide/pa-files/PAR-24-106.html

Documents

Posted documents for PAR-24-106

Potential Applicants and Partners

Awardees that have recently won grants similar to PAR-24-106

Incumbent or Similar Grants

Grants similar to PAR-24-106

Similar Active Opportunities

Open grant opportunities similar to PAR-24-106